The latest report by IMARC Group, titled" Dengue Testing Market Report by Test Type (ELISA-based Tests, RT-PCR based Tests, Dengue IgG/IgM Rapid Test, and Others), End User (Hospitals, Diagnostic Centers, and Others), and Region 2024-2032", offers a comprehensive analysis of the industry, which comprises insights on the market. The global dengue testing market size reached US$ 584.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 879.0 Million by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.

Factors Affecting the Growth of the Dengue Testing Industry:

• Increasing Incidence of Dengue Fever:

The rising incidence of dengue fever is a primary driver for the global dengue testing market. Dengue fever, a mosquito-borne viral disease, has seen a significant increase in cases over the past few decades, particularly in tropical and subtropical regions. The World Health Organization (WHO) reports that the incidence of dengue has grown dramatically around the world in recent years, with about half of the global population now at risk. This increase in cases can be attributed to several factors, including urbanization, climate change, and increased travel and trade, which facilitate the spread of the Aedes mosquitoes that transmit the virus. Consequently, there is a growing demand for effective and efficient diagnostic tests to identify dengue infections early and accurately.

• Significant Technological Advancements in Diagnostic Testing:

Technological advancements in diagnostic testing are another significant factor propelling the global dengue testing market. Traditional methods of dengue diagnosis, such as serological tests and viral isolation, often require significant time and specialized laboratory facilities. However, recent innovations in diagnostic technologies have led to the development of more rapid, accurate, and accessible testing methods. For instance, molecular diagnostic techniques such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs) offer high sensitivity and specificity, allowing for the early detection of dengue virus even in low viral load scenarios. Additionally, point-of-care (POC) testing devices have become increasingly popular due to their convenience and ability to provide quick results without the need for extensive laboratory infrastructure.

• Government Initiatives and Public Health Programs:

Government initiatives and public health programs play a crucial role in driving the global dengue testing market. Recognizing the growing threat posed by dengue fever, many governments and international health organizations have launched comprehensive programs aimed at controlling the spread of the disease and improving diagnostic capabilities. These initiatives often include funding for research and development of new diagnostic tests, subsidies for healthcare providers to adopt advanced testing technologies, and public awareness campaigns to educate communities about the importance of early diagnosis and preventive measures. Additionally, governments in dengue-endemic regions have been investing in the establishment of robust healthcare infrastructures and diagnostic laboratories to enhance their capacity to manage dengue outbreaks.

For an in-depth analysis, you can request a sample copy of the report: https://www.imarcgroup.com/dengue-testing-market/requestsample

Leading Companies Operating in the Global Dengue Testing Market

• Abbott Laboratories
• Abnova Corporation
• CerTest Biotec S.L.
• DiaSorin S.p.A.
• F. Hoffmann-La Roche AG
• InBios International Inc.
• NovaTec Immundiagnostica GmbH
• OriGene Technologies Inc.
• PerkinElmer Inc.
• Quest Diagnostics Incorporated
• Thermo Fisher Scientific Inc.

Dengue Testing Market Report Segmentation: 

By Test Type:

• ELISA-based Tests
• RT-PCR based Tests
• Dengue IgG/IgM Rapid Test
• Others

ELISA-based tests dominate the market due to their high sensitivity, specificity, and ability to simultaneously process large numbers of samples efficiently, making them a preferred choice for dengue diagnosis. 

By End User:

• Hospitals
• Diagnostic Centers
• Others

Diagnostic centers hold maximum number of shares due to their specialized capabilities, advanced testing technologies, and centralized role in early detection and accurate diagnosis of the disease.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

Region-wise, the market has been segmented into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa. 

Global Dengue Testing Market Trends:

The increasing healthcare expenditure in both developed and developing countries significantly drives the global dengue testing market. As countries allocate more funds to improve their healthcare infrastructure, there is a corresponding rise in investments in advanced diagnostic technologies and facilities. This increase in spending enables healthcare providers to adopt more sophisticated and accurate dengue testing methods, enhancing their capacity to diagnose and manage dengue fever effectively. Additionally, higher healthcare expenditure often correlates with better access to medical services and diagnostic tests for the general population. Governments and private entities are more likely to support initiatives that improve disease surveillance and diagnostic capabilities, which is crucial for managing outbreaks of mosquito-borne diseases such as dengue.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic, and technological developments for business leaders in pharmaceutical, industrial, and high-technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology, and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145